Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: A randomized, double-blind, placebo-controlled study

Drugs and Aging

Volumn 26, Issue 7, 2009, Pages 585-593

  Enajat, Morteza ^a   Teerenstra, Steven ^a   Van Kuilenburg, Janet T ^a   Van Sorge Greve, Aty H N ^b   Albers Akkers, Marjo T H ^b   Verheugt, Freek W A ^a   Pop, Gheorghe A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Anticoagulation Outpatient Clinic   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; EZETIMIBE; PHENPROCOUMON; PLACEBO;

ADD ON THERAPY; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; MALE; MULTICENTER STUDY; MYALGIA; NEUROIMAGING; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MEDICATION ADHERENCE; PLACEBO EFFECT;

EID: 70349090525     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/10558450-000000000-00000     Document Type: Article

References (19)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991; 22: 983-988
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-1564
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457
4. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002; 288: 2441-2448
5. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46
6. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559
7. Ballantyne CM, Houri J, Notarbartolo A, et al. Primary hypercholesterolemia: A prospective, randomized, double-blind trial. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 2003; 107: 2409-2415
8. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-2475
9. Kosoglou T, Statkevich P, Johnson A. Ezetimibe, a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-494
10. Stern R, Abel R, Gibson GL, et al. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997; 37: 1062-1064
11. Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis. Ann Intern Med 2006 Mar 7; 144 (5): 326-336
12. Schnegg M, Lauterburg BH. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986; 3 (2): 164-171
13. Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-911
14. Brown WV. Safety of statins. Curr Opin Lipidol 2008 Dec; 19 (6): 558-562
15. Brown H, Prescott R. Applied mixed models in medicine. Chichester: John Wiley and Sons, 1999
16. Michniewicz BM, Black AE, Sinz MW, et al. In vitro and in vivo metabolism of atorvastatin [abstract no. CI-981]. Sixth North American Meeting of ISSX (International Society for the Study of Xenobiotics); 1994 Oct 23-27; Raleigh (NC)
17. Grau E, Perella M, Pastor E. Simvastatin-oral anticoagulant interaction. Lancet 1996; 347: 405-406
18. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-215
19. Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147: 1-9